NCT06111014TerminatedPhase 3
Continuation Study for Latozinemab
A Continuation Study of Latozinemab in Participants With Neurodegenerative Disease
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
- Status (registry)
- Terminated
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 17 (actual)
- First submitted
- 18 Oct 2023
- Start date
- 8 Dec 2023
- Primary completion date
- 1 Sept 2025
- Lead sponsor
- Alector Inc.
- NCT number
- NCT06111014
- EU CT number
- 2023-506805-20-00
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
- Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.
Who the study is looking for
- Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).
- Has successfully completed participation in their parent latozinemab study.
- Female participants must be nonpregnant and nonlactating.
- Male participants must agree to acceptable contraception use.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (18)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZ Leuven | Leuven | Belgium | Unknown status |
| Parkwood Institute | London | Canada | Unknown status |
| Sunnybrook Health Sciences Centre | Toronto | Canada | Unknown status |
| Universitätsklinikum Ulm - Leimgrubenweg 12-14 | Ulm | Germany | Unknown status |
| Groupe Hospitalier Pitie - Salpetriere | Paris | France | Unknown status |
| University College London | London | United Kingdom | Unknown status |
| IRCCS - Centro S. Giovanni di Dio Fatebenefratelli | Brescia | Italy | Unknown status |
| Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico -Via Fracesco Sforza 35 | Milan | Italy | Unknown status |
| Azienda Ospedaliero - Universitaria di Modena Policlinico | Modena | Italy | Unknown status |
| Erasmus MC -Dr. Molewaterplein 40 | Rotterdam | Netherlands | Unknown status |
| Centro Hospitalar E Universitário de Coimbra EPE | Coimbra | Portugal | Unknown status |
| Centro Hospitalar Universitário Lisboa Norte, EPE., Hospital de Santa Maria | Lisbon | Portugal | Unknown status |
| Karolinska Universitetssjukhuset Huddinge | Huddinge | Sweden | Unknown status |
| University of Cincinnati Gardner Neuroscience Institute | Cincinnati | United States | Unknown status |
| Irving Institute for Clinical and Translational Research | New York | United States | Unknown status |
| University of Pennsylvania | Philadelphia | United States | Unknown status |
| Dignity Health - Arizona | Phoenix | United States | Unknown status |
| Mayo Comprehensive Cancer Center - PPDS | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.